arthritis cancer
arthritis medication that is causing cancer in young people?
In the counter medications are accused of causing cancer in children and young adults was an article on page three of the Ottawa Times, a document from Illinois What should have been on page two. The article originated in Washington with the FDA as the sourse
These are not OTC drugs, but those prescribed for young people suffering from juvenile rheumatoid arthritis or Crohn's disease. Drugs are suspected: Remicade (infliximab), Enbrel (etancercept), Humira (adalimumab), Cimzia (certolizumab) and Simponi (golimumab). Http: / / www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm For Immediate Release: 4 August 2009 of the consumer: 888-INFO-FDA FDA: Cancer of required warnings on TNF blockers The Food and Drug Administration U.S. is demanding stronger warnings in the prescribing information for a class of drugs known as TNF blockers. The warnings, including discounted cash warning, highlighting the increased risk of cancer in children and adolescents receiving these drugs to treat juvenile rheumatoid arthritis, disease inflammatory bowel disease, Crohn's disease and other inflammatory diseases. In addition, FDA is working with manufacturers to explore new ways to further define cancer risk in children and adolescents who use these drugs. TNF blockers target and neutralize the tumor necrosis factor alpha (TNF-α), a protein that when overproduced in the body due to chronic inflammatory diseases, can cause inflammation and damage to bones, cartilage and tissue. Drugs in this class include Remicade (infliximab), Enbrel (etancercept), Humira (adalimumab), Cimzia (certolizumab) and Simponi (golimumab). Today's action is based on the realization of an investigation by the FDA first announced in June 2008. An analysis of U.S. reports of cancer in children and adolescents treated with TNF-blockers showed an increased risk of cancer, which occurs after 30 months of treatment on average. About half of the cancers were lymphomas, a type of cancer that affects cells the immune system. Some of the cancers observed were fatal. Additional required updates to the prescribing information include the incorporation of reports of psoriasis associated with the use of TNF blockers.
